Acurx Pharmaceuticals, Inc. ACXP
Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) is an infectious disease drug developer. Its lead program, ibezapolstat (ACX-362E), is in Phase 2 for Clostridioides difficile infection (CDI). Its next catalyst on record is ibezapolstat: First patient enrollment in open-label pilot trial in multiply recurrent CDI (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ibezapolstat — First patient enrollment in open-label pilot trial in multiply recurrent CDI (Q4 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ibezapolstat (ACX-362E) | C. difficile infection | small molecule | Phase 2 |
| ibezapolstat open-label pilot | multiply recurrent CDI (rCDI) | small molecule | Phase 2 |
| ACX-375C | MRSA, VRE, PRSP, anthrax | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.